Drug intelligence / Profile preview

GSK610677

Development stage: Phase 1
Lead developer: GSK
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

GSK610677 is an investigational inhaled therapy developed by GSK (formerly GlaxoSmithKline) for the treatment of chronic obstructive pulmonary disease (COPD). It has been studied in phase I clinical trials to assess its safety and tolerability in escalating single inhaled doses. The precise mechanism of action for GSK610677 remains undefined, and it is classified broadly as an antiasthmatic agent. As of the latest available information, there have been no recent reports of further development or advancement beyond early-phase clinical studies[1][2][4].

Other names: GSK 610677GSK610677GSK-610677610677

Beyond the preview

Go deeper on GSK610677.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK610677.

Explore the full profile